Recursion Pharmaceuticals (RXRX) Other Working Capital Changes (2020 - 2026)

Recursion Pharmaceuticals has reported Other Working Capital Changes for 7 years, with the latest figure at -$14.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes fell 51.06% year-over-year to -$14.7 million; the trailing twelve-month figure through Mar 2026 stood at -$37.9 million (down 927.45% YoY), and the FY2025 full-year result was -$32.9 million, down 642.56% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$14.7 million, down from -$2.9 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $126.8 million in Q3 2022, with the low at -$124.0 million in Q4 2022.
• Historically, Other Working Capital Changes has averaged -$5.2 million across 5 years, with a median of -$4.8 million in 2025.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes surged 5468.63% — and 2023, when it slumped 14175.29%.
• Recursion Pharmaceuticals' Other Working Capital Changes stood at -$124.0 million in 2022, then jumped by 65.8% to -$42.4 million in 2023, then jumped by 167.07% to $28.4 million in 2024, then slumped by 110.28% to -$2.9 million in 2025, then plunged by 404.14% to -$14.7 million in 2026.
• The last three Other Working Capital Changes figures came in at -$14.7 million (Q1 2026), -$2.9 million (Q4 2025), and -$6.6 million (Q3 2025), per Business Quant data.